Recent Quotes (30 days)

You have no recent quotes
chg | %

BTG plc  

(Public, LON:BTG)   Watch this stock  
Find more results for LON:BGC
+1.52 (0.24%)
Aug 24 - Close
LON real-time data - Disclaimer
Currency in GBX unless noted
Range 629.50 - 637.00
52 week 504.00 - 739.50
Open 629.50
Vol / Avg. 302,376.00/600,919.00
Mkt cap 2,438.79M*
P/E 40.65
Div/yield     -
EPS 0.16*
Shares 383.00M
Beta     -
Inst. own     -
Nov 15, 2016
Half Year 2017 BTG PLC Earnings Release - 8:00am GMT - Add to calendar
Jul 14, 2016
BTG PLC Annual Shareholders Meeting
Jul 14, 2016
BTG PLC Interim Management Statement Release
Jun 7, 2016
BTG PLC at Jefferies Healthcare Conference

Key stats and ratios

Q1 (Mar '16) 2016
Net profit margin 4.22% 13.52%
Operating margin 7.25% 12.25%
EBITD margin - 21.94%
Return on average assets 1.65% 5.51%
Return on average equity 2.22% 7.53%
Employees 1,182 -
CDP Score - 81 D


5 Fleet Place
United Kingdom - Map
+44-20-75750000 (Phone)
+44-20-75750010 (Fax)

Website links

External links

Analyst Estimates - BusinessWeek
Options - MarketWatch
Director Dealings - Yahoo Finance


BTG plc is a specialist healthcare company. The Company operates in three business segments: Interventional Medicine (IM) (oncology, vascular and pulmonology products), Specialty Pharmaceuticals (antidote products) and Licensing (royalties from licensed assets). The Company's Interventional Medicine segment offers a portfolio of interventional medicine products that are designed to advance the treatment of liver tumors, advanced emphysema, severe blood clots and varicose veins. The Company's Specialty Pharmaceuticals segment offers a portfolio of antidote products that alleviate toxicity and treat rare conditions. The Company's Licensing segment receives royalties relating to the sales of products that are subject to intellectual property and license agreements between the Company and various partners. The Company's subsidiaries include BTG International (Holdings) Ltd, Provensis Ltd, BTG International Ltd and BTG Employee Share Schemes Ltd, among others.

Officers and directors

Dame Pamela Louise Makin Ph.D. Chief Executive Officer, Executive Director
Age: 54
Rolf B. Soderstrom Chief Financial Officer, Executive Director
Melanie G. Lee Ph.D. Chief Scientific Officer
Age: 57
Paul Mussenden Company Secretary
Garry Andrew Watts Non-Executive Chairman of the Board
Age: 59
Susan Elizabeth Foden Ph.D. Non-Executive Director
Age: 62
Giles F. B. Kerr Senior Independent Non-Executive Director
Ian F. R. Much Independent Non-Executive Director
W. James O'Shea Independent Non-Executive Director